May 24, 2024

hh5800/iStock by way of Getty Pictures

Offers and Financings

Shanghai’s Elpiscience Biopharma has fashioned a $1.7 billion collaboration with Japan’s Astellas Pharma (OTCPK:ALPMF, TSE: 4503) to develop a novel bispecific macrophage engager, ES019, together with an unspecified program (see story